Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elotuzumab + lenalidomide + autologous stem cell transplantation
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Stem Cell Therapies → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
elotuzumab + lenalidomide + autologous stem cell transplantation is a combination therapeutic regimen investigated for the treatment of symptomatic multiple myeloma. This regimen integrates elotuzumab (Empliciti), a humanized monoclonal antibody targeting SLAM family member 7 (SLAMF7), with lenalidomide (Revlimid), an immunomodulatory imide drug (IMiD) that binds to cereblon to induce the degradation of transcription factors Ikaros and Aiolos. The protocol involves induction therapy, followed by high-dose chemotherapy (typically melphalan) and autologous stem cell transplantation (ASCT), with subsequent maintenance therapy using elotuzumab and lenalidomide. The combination aims to leverage the direct activation of natural killer cells and the tagging of myeloma cells by elotuzumab alongside the tumor-inhibiting and immune-modulating effects of lenalidomide to improve outcomes following transplant.
- Other names
- Elotuzumab + Lenalidomide + ASCT
02
Targets
CRBN (Cereblon)SLAMF7 (Signaling lymphocytic activation molecule family member 7)
Beyond the preview
Go deeper on elotuzumab + lenalidomide + autologous stem cell transplantation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elotuzumab + lenalidomide + autologous stem cell transplantation.